CPZ

Across TCGA pan-cancer cohorts, CPZ Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated CPZ data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher CPZ Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CPZ expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BRCA, ESCA, and LUAD are the cancer types where CPZ Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.553	0.963	<.001	48	view →
ESCA	DFS	Median	All	0.165	0.541	<.001	36	view →
LUAD	DFS	Median	II,III,IV	0.348	0.732	.001	19	view →
LIHC	OS	Median	II,III,IV	0.104	0.702	<.001	15	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
TGCT	DFS	Median	All	0.151	0.801	.026	6	view →
SCLC	OS	Median	All	0.082	0.653	.002	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	II,III,IV	0.936	0.722	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

CPZ–BRCA (OS)

Open the BRCA breakdown →